Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effect of defibrotide on platelet function

O N Ulutin1, S Balkuv-Ulutin, B Bezer-Göker

  • 1Thrombosis and Hemostasis Research Center, Cerrahpaşa Medical School of Istanbul University, Turkey.

Seminars in Thrombosis and Hemostasis
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of biocompatible carriers with vitamin D and platelet-rich plasma (PRP) on bone defects.

Hippokratia·2024
Same author

Coronavirus 19 presenting with atypical Sweet's syndrome.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

The association between gastroesophageal flap valve function and gastroesophageal reflux symptoms.

Acta gastro-enterologica Belgica·2018
Same author

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Polyurethane/hydroxypropyl cellulose electrospun nanofiber mats as potential transdermal drug delivery system: characterization studies and in vitro assays.

Artificial cells, nanomedicine, and biotechnology·2016
Same author

[Diplopia 10 years after scleral buckling surgery].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2016

Defibrotide modulates endothelial cells, increasing beneficial t-PA and PGI2 while decreasing PAI. It also inhibits platelet activation, offering therapeutic potential for thrombosis and vascular disorders.

Area of Science:

  • Pharmacology
  • Vascular Biology
  • Biochemistry

Background:

  • Defibrotide is a polydeoxyribonucleotide with known effects on endothelial cell function.
  • Existing research suggests defibrotide influences key components of the coagulation and platelet activation pathways.

Purpose of the Study:

  • To elucidate the multifaceted mechanisms by which defibrotide exerts its therapeutic effects.
  • To investigate defibrotide's impact on endothelial function, coagulation factors, and platelet activity.

Main Methods:

  • Assessed changes in tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI), and prostaglandin I2 (PGI2) in human subjects.
  • Evaluated defibrotide's antithrombotic effects in animal models.
  • Examined defibrotide's influence on platelet function, including aggregation, adhesion, and secretion, in both animal and human studies.

Related Experiment Videos

  • Measured platelet cyclic AMP (cAMP), malonyl dialdehyde (MDA), thromboxane B2 (TXB2), PF-4, and beta-thromboglobulin (beta-TG) levels.
  • Investigated the effect of defibrotide on glucose transport in platelets from atherosclerotic patients.

    • Main Results:

    • Defibrotide increased t-PA and PGI2 levels and decreased PAI levels in humans.
    • Demonstrated significant antithrombotic effects in animal models, with synergistic action with heparin.
    • Inhibited platelet function, reducing aggregate formation, adhesion, and secretion of platelet factors (PF-4, beta-TG).
    • Observed increased platelet cAMP and decreased MDA and TXB2 formation.
    • Partially corrected platelet glucose transport defects in atherosclerotic patients.

    Conclusions:

    • Defibrotide exhibits a beneficial profile for treating conditions like deep venous thrombosis (DVT), peripheral obliterative vascular disorder (POVD), stroke, vasculitis, and thromboembolism.
    • The drug's mechanism involves modulating endothelial function and inhibiting platelet activation, independent of direct anticoagulant effects.
    • Defibrotide shows promise in improving vascular health and preventing thrombotic events through its combined actions.